SGN-75

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Carcinoma, Renal CellLymphoma, Non-HodgkinRenal Cell Carcinoma

Phase 1

A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

CompletedNCT01015911

Seagen Inc.Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin

Start: 2009-11-30End: 2012-03-31Updated: 2014-12-18

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

TerminatedNCT01677390

Seagen Inc.Renal Cell Carcinoma

Start: 2012-08-31End: 2013-12-31Updated: 2014-01-28